Recursion Pharmaceuticals, Inc.
RXRXNASDAQHealthcare● Active
$3.32
+$0.00(+0.07%)
Market Cap$1.5B
P/E Ratio—
52W High$7.18
52W Low$2.77
Recursion Pharmaceuticals, Inc. (RXRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RXRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $74.68M | $58.84M | $43.88M | $39.68M | $10.00M |
| Cost of Revenue | $120.95M | $45.24M | $42.59M | $48.27M | $0.00M |
| Gross Profit | ($46.27M) | $13.60M | $1.29M | ($8.59M) | $10.00M |
| Gross Margin %(computed) | -61.96% | 23.12% | 2.94% | -21.66% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $425.27M | $314.42M | $241.23M | $155.70M | $135.27M |
| G&A Expenses | $176.59M | $178.18M | $110.82M | $81.60M | $57.68M |
| Total Operating Expenses | $601.86M | $492.61M | $351.35M | $237.13M | $192.78M |
| Operating Income | ($648.13M) | ($479.00M) | ($350.06M) | ($245.73M) | ($182.78M) |
| Operating Margin %(computed) | -867.87% | -814.09% | -797.84% | -619.26% | — |
| Interest Income | $22.79M | $15.76M | $19.12M | $6.25M | $0.07M |
| Interest Expense | $1.81M | $1.57M | $0.10M | $0.06M | $2.95M |
| Income Before Tax | ($644.89M) | ($464.79M) | ($332.13M) | ($239.48M) | ($186.48M) |
| Income Tax Expense | ($0.14M) | ($1.13M) | ($4.06M) | $0.00M | $0.00M |
| Net Income | ($644.76M) | ($463.66M) | ($328.07M) | ($239.48M) | ($186.48M) |
| Net Margin %(computed) | -863.35% | -788.02% | -747.71% | -603.50% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.05 |
| Wtd Avg Shares | 447.45M | 274.21M | 207.85M | 175.54M | 170.27M |
| EBITDA | ($559.38M) | ($426.72M) | ($307.63M) | ($227.66M) | ($175.12M) |
| EBITDA Margin %(computed) | -749.03% | -725.24% | -701.13% | -573.74% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Recursion Pharmaceuticals, Inc. data
About Recursion Pharmaceuticals, Inc. (RXRX) Income Statement
Recursion Pharmaceuticals, Inc. (RXRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RXRX reported revenue of $0.07B, gross profit of ($0.05B) (gross margin -61.96%), and net income of ($0.64B) — a net profit margin of -863.35%.
Frequently asked questions
RXRX · 4 questionsRecursion Pharmaceuticals, Inc. (RXRX) reported revenue of $0.07B for 2025, up 26.9% year-over-year.
RXRX revenueRXRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08